Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.
Article
PubMed
Google Scholar
Chen X, Liu Y, Røe OD, Qian Y, Guo R, Zhu L, et al. Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. PLoS One. 2013;8(3):e59314.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gaughan EM, Costa DB. Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol. 2011;3(3):113–25.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jin T, Jin J, Shang Y, Zhang S, Yu K, Piao Y, et al. Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer. BMC Cancer. 2014;14:191.
Article
PubMed
PubMed Central
Google Scholar
Vasilious V, Rose D, Nebert DW. Update of the NAD(P)H: quinone oxidoreductase (NQO) gene family. Hum Genomic. 2006;2(5):329–35.
Article
Google Scholar
Buranrat B, Prawan A, Kukongviriyapan U, Kongpetch S, Kukongviriyapan V. Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells. World J Gastroenterol. 2010;16(19):2362–70.
Article
CAS
PubMed
PubMed Central
Google Scholar
Siegel D, Gustafson DL, Dehn DL, Han JY, Boonchoong P, Berliner LJ, et al. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavengar. Mol Pharmacol. 2004;65(5):1238–47.
Article
CAS
PubMed
Google Scholar
Siegel D, Bolton EM, Burr JA, Liebler DC, Ross D. The reduction of alpha-tocopherolquinone by human NAD(P)H: quinone oxidoreductase: the role of alpha-tocopherolhydrolquinone as a cellular antioxidant. Mol Pharmacol. 1997;52(2):300–5.
CAS
PubMed
Google Scholar
Siegel D, Ross D. Immunodetection of NAD(P)H: quinone oxidoreductase 1 (NQO1) in human tissues. Free RadicBiol Med. 2000;29(2–3):246–53.
Article
CAS
Google Scholar
Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(5):979–87.
Article
CAS
PubMed
Google Scholar
Awadallah NS, Dehn D, Shah RJ, Russell Nash S, Chen YK, Ross D, et al. NQO1 expression in pancreatic cancer and its potentail use as a biomarker. ApplImmunohistochem Mol Morphol. 2008;16(1):24–31.
CAS
Google Scholar
Buranrat B, Chau-in S, Prawan A, Puapaoroj A, Zeekpudsa P, Kukongviriyapan V. NQO1 expression correlates with cholangiocarcinoma prognosis. Asian Pac J Cancer Pre. 2012;13(Suppl):131–6.
Google Scholar
Garate M, Wani AA, Li G. The NAD(P)H:Quinone Oxidoreductase 1 inducescell cycle progression and proliferation of melanoma cells. Free RadicBiolMed. 2010;48(12):1601–9.
Article
CAS
Google Scholar
Ernster L, Lindberg O. Animal mitochondria. Annu Rev Physiol. 1958;20:13–42.
Article
CAS
PubMed
Google Scholar
Nioi P, Hayes JD. Contribution of NAD(P)H: quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat Res. 2004;555(1–2):149–71.
Article
CAS
PubMed
Google Scholar
Girolami F, Abbadessa G, Racca S, Spaccamiglio A, Piccione F, Dacasto M, et al. Time-dependent acetylsalicylic acid effects on liver CYP1A and antioxidant enzymes in a rat model of 7,12-dimethylbenzanthracene(DMBA)-induced mammary carcinogenesis. Toxicol Lett. 2008;181(2):87–92.
Article
CAS
PubMed
Google Scholar
Nagata M, Kimura T, Suzumura T, Kira Y, Nakai T, Umekawa K, et al. C609Tpolymorphism of NADPH Quinone Oxidoreductase 1 Correlates clinicalhematological toxicities in lung cancer patients treated with Amrubicin. Clin Med Insights Oncol. 2013;7:31–9.
CAS
PubMed
PubMed Central
Google Scholar
Malik MA, Zargar SA, Mittal B. Role of NQO1 609C > T and NQO2-3423G > A gene polymorphisms in esophageal cancer risk in Kashmir valley andmeta analysis. Mol Biol Rep. 2012;39(9):9095–104.
Article
CAS
PubMed
Google Scholar
Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjäkoski K, et al. NAD(P)H: quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet. 2008;40(7):844–53.
Article
CAS
PubMed
Google Scholar
Asher G, Lotem J, Cohen B, Sachs L, Shaul Y. Regulation of p53 stability and p53-dependent apoptosis by NADH quinoneoxidoreductase 1. Proc NatlAcadSci U S A. 2001;98(3):1188–93.
Article
CAS
Google Scholar
Asher G, Bercovich Z, Tsvetkov P, Shaul Y, Kahana C. 20S proteasomal degradation of ornithine decarboxylase is regulated by NQO1. Mol Cell. 2005;17(5):645–55.
Article
CAS
PubMed
Google Scholar
Yang Y, Zhang Y, Wu Q, Cui X, Lin Z, Liu S, et al. Clinical implications of high NQO1 expression inbreast cancers. J Exp Clin Cancer Res. 2014;33:14.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ma Y, Kong J, Yan G, Ren X, Jin D, Jin T, et al. NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix. BMC Cancer. 2014;14:414.
Article
PubMed
PubMed Central
Google Scholar
Lin L, Qin Y, Jin T, Liu S, Zhang S, Shen X, et al. Significance of NQO1overexpression for prognostic evaluation of gastric adenocarcinoma. Exp Mol Pathol. 2014;96(2):200–5.
Article
CAS
PubMed
Google Scholar
Awadallah NS, Dehn D, Shah RJ, Russell Nash S, Chen YK, Ross D, et al. NQO1 expression in pancreatic cancer and its potential use as a biomarker. Appl Immunohistochem Mol Morphol. 2008;16(1):24–31.
CAS
PubMed
Google Scholar
Lyn-Cook BD, Yan-Sanders Y, Moore S, Taylor S, Word B, Hammons GJ. Increased levels of NAD(P)H: quinoneoxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas. Cell Biol Toxicol. 2006;22(2):73–80.
Article
CAS
PubMed
Google Scholar
Malkinson AM, Siegel D, Forrest GL, Gazdar AF, Oie HK, Chan DC, et al. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cl. Cancer Res. 1992;52(17):4752–7.
CAS
PubMed
Google Scholar
Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. Identification of an NAD(P)H: quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics. 1995;5(4):199–206.
Article
CAS
PubMed
Google Scholar
Heller G, Zielinski CC, Zochbauer-Muller S. Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev. 2010;29(1):95–107.
Article
CAS
PubMed
Google Scholar
Mikami K, Naito M, Ishiguro T, Yano H, Tomida A, Yamada T, et al. Immunological quantitation of DT-diaphorase in carcinoma cell lines and clinical colon cancers: advanced tumors express greater levels of DT-diaphorase. Jpn J Cancer Res. 1998;89(9):910–5.
Article
CAS
PubMed
Google Scholar
Kim HC, Song JS, Lee JC, Lee DH, Kim SW, Lee JS, et al. Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer. Int J Clin Exp Pathol. 2014;7(10):6743–51.
CAS
PubMed
PubMed Central
Google Scholar
Workman P. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res. 1994;6(10–11):461–75.
CAS
PubMed
Google Scholar
Park EJ, Min KJ, Lee TJ, Yoo YH, Kim YS, Kwon TK. β-Lapachoneindcuces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells. Cell Death Dis. 2014;5:e1230.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kung H, Weng T, Liu Y, Lu K, Chau Y. Sulindac Compounds Facilitate the Cytotoxicity of β-Lapachone by Up-Regulation of NAD(P)H Quinone Oxidoreductase in Human Lung Cancer Cells. PLoS One. 2014;9(2):e88122.
Article
PubMed
PubMed Central
Google Scholar
Huang X, Dong Y, Bey E. An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis. Cancer Res. 2012;72(12):3038–47.
Article
CAS
PubMed
PubMed Central
Google Scholar